Table 2 Excess risk (%) of at least 7% weight gain associated with changes in doses and antipsychotics

From: Risk of weight gain for specific antipsychotic drugs: a meta-analysis

Antipsychotic Paliperidone Risperidone Olanzapine
Dose, mg 0 to 300 0 to 80 0 to 420
Excess risk, % 3.2 (1.5, 5.3) 1.3 (−2.3, 6.1) 12.2 (1.4, 27.2)
%a 4.6 (2.6, 6.7) 6 (−2.3, 24.9) 12.6 (6.2, 20)
Dose, mg 300 to 975 80 to 427 420 to 707
Excess risk, % 14.3 (5.5, 26.9) 13 (−3, 70.3) 16.7 (1.2, 34.9)
%a 0 0 0
Dose, grams CPZ   0 to 10  
Excess risk, % 1.4 (0.7, 2.3) 4.5 (−3.8, 24.4) 16.1 (1.7, 36.4)
%a 4.6 (2.6, 6.7) 6 (−2.3, 24.9) 12.6 (6.2, 20)
Dose, grams CPZ   0 to 20  
Excess risk, % 3.2 (1.5, 5.3) 12.6 (−5, 70) 46.8 (3.9, 83.6)
%a 4.6 (2.6, 6.7) 6 (−2.3, 24.9) 12.6 (6.2, 20)
  1. The first two rows provide casual estimates across doses but within treatment drugs, in terms of their original scale (milligrams of each drug). Thus, the excess risk associated with an increase in cumulative dose from 0 mg to the 50th percentile and from the 50th to 90th percentile of each drug is shown. Estimates can be compared across drugs when reported in CPZ equivalent units as in the 3rd and 4th row
  2. aDenotes the as-randomized estimates that assume no dose effect